Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug popularity and research into Alzheimer’s.
Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance.
The company launched 7.5 mg and 10 mg vials of tirzepatide, sold under the brand name Zepbound, which typically cost $599 and $699, respectively. However, they are now available for $499 per month for patients paying without insurance. This applies to the first fill and all refills that are delivered every 45 days.
Additionally, the company lowered the prices of the 2.5 mg and 5 mg vials to $349 and $499 per month, respectively.
WEIGHTWATCHERS CEO SIMA SISTANI OUT IN ABRUPT EXIT, EMBRACED WEIGHT LOSS DRUGS
The company, which has seen a significant boost in profits from Zepbound…
